产品
编 号：F763052
分子式：C120H146N26O36
分子量：2528.6
分子式：C120H146N26O36
分子量：2528.6
产品类型
规格
价格
是否有货
结构图
CAS No: 2857098-72-5
产品详情
生物活性：
PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research.
体内研究：
PBI-6DNJ (0-2 mg/kg, Orally, once) reduces postprandial blood glucose (PBG) levels. PBI-6DNJ (2.0 mg/kg, Orally, daily for 7 day) has good biocompatibility and no damage to mice.Animal Model:C57BL-6J mice (twenty-eight, 4-5 weeks old, 18-20 g)
Dosage:0.5, 1.0 and 2.0 mg/kg
Administration:Orally, once
Result:Reduced postprandial blood glucose (PBG) level, resulting in 24.41 ± 3.02%, 34.65 ± 9.66%, and 37.77 ± 4.35% of decreases in PBG levels at the doses of 0.5, 1.0 and 2.0 mg/kg, respectively.
Animal Model:C57BL-6J mice (twenty-eight, 4-5 weeks old, 18-20 g)
Dosage:2.0 mg/kg
Administration:Orally, daily for 7 day
Result:Resulted in increase of the level of UREA (8.63 ± 0.59 mmol/L) and decrease of the level of UA level (242.06 ± 14.77 μmol/L). No obvious differences in the levels of UREA and UA were observed. Showed a slight decrease of 0.30 mmol/L in the level of LDL. The AST level of PBI-6DNJ group (269.71 ± 39.77 U/L) was higher than that of the control group (221.38 ± 23.03 U/L), and the ALT level (59.14 ± 7.13 U/L) was lower than that of the control group (70.49 ± 8.78U/L).
PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research.
体内研究：
PBI-6DNJ (0-2 mg/kg, Orally, once) reduces postprandial blood glucose (PBG) levels. PBI-6DNJ (2.0 mg/kg, Orally, daily for 7 day) has good biocompatibility and no damage to mice.Animal Model:C57BL-6J mice (twenty-eight, 4-5 weeks old, 18-20 g)
Dosage:0.5, 1.0 and 2.0 mg/kg
Administration:Orally, once
Result:Reduced postprandial blood glucose (PBG) level, resulting in 24.41 ± 3.02%, 34.65 ± 9.66%, and 37.77 ± 4.35% of decreases in PBG levels at the doses of 0.5, 1.0 and 2.0 mg/kg, respectively.
Animal Model:C57BL-6J mice (twenty-eight, 4-5 weeks old, 18-20 g)
Dosage:2.0 mg/kg
Administration:Orally, daily for 7 day
Result:Resulted in increase of the level of UREA (8.63 ± 0.59 mmol/L) and decrease of the level of UA level (242.06 ± 14.77 μmol/L). No obvious differences in the levels of UREA and UA were observed. Showed a slight decrease of 0.30 mmol/L in the level of LDL. The AST level of PBI-6DNJ group (269.71 ± 39.77 U/L) was higher than that of the control group (221.38 ± 23.03 U/L), and the ALT level (59.14 ± 7.13 U/L) was lower than that of the control group (70.49 ± 8.78U/L).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备